Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial

• Published in: Ecancermedicalscience Vol. 16; p. 1379
• Main Authors: Franzoi, Maria Alice, Procter, Marion, Twelves, Chris, Ponde, Noam, Eiger, Daniel, Emond, Orianne, Clark, Emma, Parlier, Damien, Guillaume, Sébastien, Reaby, Linda, de Azambuja, Evandro, Bines, Jose
• Format: Journal Article
• Language: English
• Published: England Cancer Intelligence 2022
• Subjects: Breast cancer; Classification; Clinical trials; Collaboration; Geography; Medical research; Patient safety; Pharmaceutical industry; Variance analysis; Middle East; Europe; Africa; Brazil; East Asia; North Africa; Israel; Central Asia; North America; Latin America; ethics committee/institutional review board; clinical trials; regulatory approval; trial activation timelines
• ISSN: 1754-6605; 1754-6605
• DOI: 10.3332/ecancer.2022.1379

Geographic location and national income may influence access to innovation in healthcare. We aimed to study if geographical location and national income influenced the timelines to activate the global phase III APHINITY trial, evaluating adjuvant pertuzumab in patients with HER2-positive early breast cancer.
Time from regulatory authority (RA) submission to approval (RAA), time to Ethics Committee/Institutional Review Board (EC/IRB) approval, time from study approval by EC/IRB to first randomised patient and from first to last randomised patient were collected. Analyses were conducted grouping countries by geographical region or economic income classification.
Forty-one countries (of 42) had data available regarding all relevant timelines. No statistical difference was observed between the time to RAA and geographical region (
= 0.47), although there was a trend to longer time to RAA in upper middle-income economies (
= 0.07). Except for time from first to last patient randomised, there was wide variation in timelines overall and within geographical regions and economic income groups.
Geographical location and income classification did not appear to be the major drivers influencing time for clinical trial activation. Wide variability in activation timelines within geographical regions and income groups exists and is worthy of further investigation.